Citadel Advisors
CGTX icon

Citadel Advisors’s Cognition Therapeutics CGTX Stock Holding History

Citadel Advisors’s Portfolio CGTX Stock Details CGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-25,905
Closed -$19.7K – 13787
2026
Q1 		$19.7K Sell
25,905
-135,296
-84% -$157K ﹤0.01% 12674
2025
Q4 		$218K Buy
+161,201
New +$262K ﹤0.01% 10861
2024
Q3 		– Sell
-26,950
Closed -$44.7K – 14314
2024
Q2 		$44.7K Buy
+26,950
New +$53.7K ﹤0.01% 11892
2022
Q2 		– Sell
-10,504
Closed -$28K – 12968
2022
Q1 		$28K Buy
+10,504
New +$40.5K ﹤0.01% 13127

Other funds holding CGTX

BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.17B AUM 42.44% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.47B AUM 18.73% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return

Citadel Advisors's CGTX Position: Q2 2026 in Review

Citadel Advisors sold out of Cognition Therapeutics (CGTX) in Q2 2026, closing a stake of 25,905 shares — an estimated $19.7K sold.

Citadel Advisors first reported a position in CGTX in Q1 2022 and held it in 4 quarters. The position peaked at $218K in Q4 2025. 66 funds tracked by Wall St. Rank hold CGTX as of Q2 2026.

  • Citadel Advisors reported no remaining Cognition Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Citadel Advisors sold 25,905 Cognition Therapeutics shares in Q2 2026, an estimated $19.7K.
  • Citadel Advisors first reported a position in Cognition Therapeutics in Q1 2022 and held it in 4 quarters.
  • Citadel Advisors's Cognition Therapeutics position peaked at $218K in Q4 2025.
  • 66 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.